Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, BioStem Technologies's Enterprise Value is $51.50 Mil.
BioStem Technologies's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00 Mil. Therefore, BioStem Technologies's EV-to-OCF for today is .
The historical rank and industry rank for BioStem Technologies's EV-to-OCF or its related term are showing as below:
BSEM'
s EV-to-OCF Range Over the Past 10 Years
Min: -307.02 Med: -40.82 Max: 296.03
Current: 2.1
During the past 13 years, the highest EV-to-OCF of BioStem Technologies was 296.03. The lowest was -307.02. And the median was -40.82.
BSEM's EV-to-OCF is ranked worse than 79.08% of 1410
companies
in the Biotechnology industry
Industry Median: -3.625
vs BSEM: 2.10
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioStem Technologies's PE Ratio (TTM) for today is calculated as:
BioStem Technologies's share price for today is $3.21.
BioStem Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.490.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BioStem Technologies EV-to-OCF Related Terms
BioStem Technologies EV-to-OCF Historical Data
* Premium members only.
The historical data trend for BioStem Technologies's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioStem Technologies's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioStem Technologies EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioStem Technologies's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where BioStem Technologies's EV-to-OCF falls into.
BioStem Technologies's current Enterprise Value is $51.50 Mil.
BioStem Technologies's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
35GF Score
Get the complete analysis for BSEM
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSEM has been successfully added to your 
